Bevacizumab When You Are Older — or Have Other Illnesses

Age alone is not a reason to withhold bevacizumab, and there is no routine dose reduction for older patients. What matters is your overall fitness and whether you have specific conditions that bevacizumab can worsen. Older patients are more likely to carry more than one of those conditions — high blood pressure, reduced kidney function, a history of heart disease — which is why the pre-treatment assessment takes each one seriously rather than treating age as the deciding factor.

Yes, in most cases, but your blood pressure needs to be well controlled before treatment starts. Bevacizumab raises blood pressure in a proportion of patients, and those who already have hypertension are watched more closely throughout. Your team will check it at each visit and may adjust your antihypertensive medicines during treatment. Poorly controlled hypertension can lead to a pause — it is a manageable barrier, not a permanent one.

Kidney function matters because bevacizumab can cause protein to leak into the urine, adding strain to kidneys that are already working hard. Your team will check your urine for protein before each cycle. If the amount reaches a level your oncologist considers significant — as set out in ESMO and NCCN guidance — treatment is held until it falls. This precaution applies at every cycle but matters more when your kidneys were already affected before you started.

A recent heart attack or stroke is the condition your oncologist considers most carefully. Bevacizumab is associated with a small but real increase in the risk of arterial events — clots in arteries — and that risk is higher in those who have already had one. NCCN and ASCO guidance identifies a recent arterial thromboembolism as a factor that may mean bevacizumab should be avoided or deferred. Your oncologist will weigh this against how much bevacizumab is likely to help and whether another treatment is a viable option for your cancer.

Bevacizumab can generally be given alongside anticoagulants, and many patients on blood thinners receive it without serious problems. Bevacizumab does carry a risk of bleeding, and blood thinners add to that risk, so your team will monitor you more closely and ask you to report any new or unusual bleeding promptly — including nosebleeds that are harder to stop than usual. The decision to combine the two is made case by case, based on why you are on anticoagulation and how stable your underlying condition is.

Diabetes itself does not prevent bevacizumab, but it makes monitoring your kidneys and blood pressure during treatment more important. Bevacizumab can raise blood pressure and cause protein in the urine, and diabetes independently affects both. Your team will want your blood sugar reasonably controlled before starting and will watch kidney markers alongside the usual bevacizumab checks at each visit. If you are on medicines that affect your kidneys, tell your oncologist before treatment begins.

Bevacizumab impairs wound healing, so your oncologist will wait until your wound has healed fully before starting it. NCCN guidance recommends a waiting period after surgery, and a similar pause before any planned procedure during treatment. The length of time your team recommends depends on the type of surgery and how your wound is healing. If you need any procedure during treatment — including a dental extraction or a biopsy — tell your team before it is booked, so they can plan the timing around it.

Call your team the same day for any new severe headache, a wound that has reopened or is not healing, blood in your urine or stools, or unexplained leg swelling and pain. Go to the emergency department without waiting for a callback if you have sudden chest pain, difficulty breathing, sudden weakness or numbness on one side of the body, slurred speech, or severe abdominal pain. Having other illnesses does not change the list of warning signs — it makes acting on them quickly even more important.